Published December 13, 2024 | Submitted v1
Discussion Paper Open

A conserved role for ALG10/ALG10B and the N-glycosylation pathway in the sleep-epilepsy axis

Abstract

Congenital disorders of glycosylation (CDG) comprise a class of inborn errors of metabolism resulting from pathogenic variants in genes coding for enzymes involved in the asparagine-linked glycosylation of proteins. Unexpectedly to date, no CDG has been described for ALG10, encoding the alpha-1,2-glucosyltransferase catalyzing the final step of lipid-linked oligosaccharide biosynthesis. Genome-wide association studies (GWAS) of human traits in the UK Biobank revealed significant SNP associations with short sleep duration, reduced napping frequency, later sleep timing and evening diurnal preference as well as cardiac traits at a genomic locus containing a pair of paralogous enzymes ALG10 and ALG10B. Modeling Alg10 loss in Drosophila, we identify an essential role for the N-glycosylation pathway in maintaining appropriate neuronal firing activity, healthy sleep, preventing seizures, and cardiovascular homeostasis. We further confirm the broader relevance of neurological findings associated with Alg10 from humans and flies using zebrafish and nematodes and demonstrate conserved biochemical roles for N-glycosylation in Arabidopsis. We report a human subject homozygous for variants in both ALG10 and ALG10B arising from a consanguineous marriage, with epilepsy, brain atrophy, and sleep abnormalities as predicted by the fly phenotype. Quantitative glycoproteomic analysis in our Drosophila model identifies potential key molecular targets for neurological symptoms of CDGs.

Copyright and License

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Funding

R.S., J.A.W., G.C.M.: NIH-NHLBI 1R01 HL146751-01A1. C.M.W. and J.A.W.: NIH 1RF1AG081475-01 G.C.M.: NIH-NIA 1R01AG065992. B.dB.: NIH-NINDS 1R01NS121874-01. J.T.L.: NIH MH104536 and NS117588. D.A.P.: NIH R35 NS122172. C.J.D.: USDA National Institute of Food and Agriculture Project 1002035 and National Science Foundation (NSF) 2210293 J.M.L.: NIH R01 HG012810 and R35 GM146839. K.G.O.: NIH R15GM155985 B.M.: NIH T32MH020068 and T32NS062443. No authors or their institutions received payment or services from a third party for any aspect of the submitted work at any time.

Conflict of Interest

S.G. is a stockholder and employee of Magnet Biomedicine. S.L.S. and R.S. are founders and stockholders of Magnet Biomedicine. B.Y. is a stockholder and employee of Sanofi. The other authors declare no competing interests.

Supplemental Material

Data Availability

Data available at Mendeley Data. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD055485.

https://doi.org/10.17632/kmf7bnxysd.1

https://doi.org/10.17632/w6jbwzvjt7.1

https://doi.org/10.17632/kn7z4z4cw5.1

Files

2024.12.11.24318624v1.full.pdf
Files (17.4 MB)
Name Size Download all
md5:e3674d21ed7221a5fce6b75e56e5d5f2
15.0 MB Preview Download
md5:f4c5742d5d0fd608eff1ba57c87321f6
659.8 kB Download
md5:3eb4f3942b03f45e80871dbf3b9d7f09
1.7 MB Preview Download

Additional details

Created:
March 5, 2025
Modified:
March 5, 2025